These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19487603)

  • 21. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost is not a barrier to implementing clopidogrel pharmacogenetics.
    Cavallari LH; Schumock GT
    Pharmacotherapy; 2012 Apr; 32(4):299-303. PubMed ID: 22461119
    [No Abstract]   [Full Text] [Related]  

  • 23. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
    Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
    Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
    Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
    Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [CYP2C19 gene polymorphism in patients with myocardial infarction who use clopidogrel].
    Galiavich AS; Valeeva DD; Minnetdinov RSh; Arkhipova AA; Akhmetov II; Galiavi RA
    Kardiologiia; 2012; 52(4):20-4. PubMed ID: 22839512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
    Gurbel PA; Tantry US; Shuldiner AR
    JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
    [No Abstract]   [Full Text] [Related]  

  • 27. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using models to predict the future: what to do when the data run out?
    Pauker SG; Goss FR
    Clin Pharmacol Ther; 2012 May; 91(5):769-71. PubMed ID: 22513311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prasugrel or clopidogrel in patients with coronary intervention].
    Schrör K
    Internist (Berl); 2009 Nov; 50(11):1293-6. PubMed ID: 19830398
    [No Abstract]   [Full Text] [Related]  

  • 30. Another view on prasugrel.
    Calatzis A
    Thromb Haemost; 2009 Jan; 101(1):12-3. PubMed ID: 19132183
    [No Abstract]   [Full Text] [Related]  

  • 31. Prasugrel versus clopidogrel.
    von Lewinski F; Riggert J; Paulus W
    N Engl J Med; 2008 Mar; 358(12):1299; author reply 1299-301. PubMed ID: 18357639
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Oberhänsli M; Lehner C; Puricel S; Lehmann S; Togni M; Stauffer JC; Baeriswyl G; Goy JJ; Cook S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):587-92. PubMed ID: 23177487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prodrug activation as a crucial difference. Prasugrel - a new ADP receptor antagonist].
    Alban S
    Pharm Unserer Zeit; 2009; 38(4):320-8. PubMed ID: 19572350
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
    Jeong YH; Park Y; Muse WC; Kwon TJ; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    J Thromb Haemost; 2012 Aug; 10(8):1685-8. PubMed ID: 22612904
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
    Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
    J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.
    Guzauskas GF; Hughes DA; Bradley SM; Veenstra DL
    Clin Pharmacol Ther; 2012 May; 91(5):829-37. PubMed ID: 22453194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 38. Prasugrel STEMI subgroup analysis.
    Shil AB; Strohm MP
    Lancet; 2009 May; 373(9678):1846; author reply 1846-8. PubMed ID: 19482212
    [No Abstract]   [Full Text] [Related]  

  • 39. Controversies in the use & implementation of drug-eluting stent technology.
    Itagaki BK; Brar SS
    Indian J Med Res; 2012 Dec; 136(6):926-41. PubMed ID: 23391788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Do genetic factors reduce the effects of clopidogrel?].
    Scharf RE
    Dtsch Med Wochenschr; 2011 Apr; 136(15):786. PubMed ID: 21469049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.